Key result
Oxidized low-density lipoprotein weakly activated platelets at an early stage, but subsequently inhibited platelet aggregation and β-thromboglobulin secretion compared with unoxidized LDL.
Why the study?
This study aimed to examine whether oxidized low-density lipoprotein facilitates platelet aggregation, a contributor to cardiovascular disease development.
Does oxidized low-density lipoprotein (oxLDL) facilitate platelet aggregation?
Does oxidized low-density lipoprotein (oxLDL) facilitate platelet aggregation?
Highly oxidized LDL appears to inhibit rather than facilitate platelet aggregation and β-TG secretion after an initial weak activation.
OxLDL inhibits platelet aggregation after weak early activation in animals; hypothesis-generating and should not change practice.
OBJECTIVE: This study aimed to examine whether oxidized low-density lipoprotein (oxLDL) facilitates platelet aggregation, which is one cause for development of cardiovascular disease. METHODS: The susceptibility of platelets to aggregation was monitored by light transmittance aggregometry and a laser light scattering method using low-density lipoprotein (LDL) and oxLDL as agonists. β-thromboglobulin (β-TG) levels released from platelets were also measured after incubation with or without oxLDL. RESULTS: Platelet aggregation was suppressed by oxLDL as estimated by maximum light transmission. Additionally, adenosine diphosphate-induced further aggregation was slightly reduced by the presence of oxLDL. Aggregation levels of a low number of platelets, which was determined by the laser light scattering method, were lower upon addition of oxLDL compared with unoxidized LDL. After a short time of incubation, oxLDL increased secreted β-TG levels in platelet-rich plasma. However, further incubation with oxLDL caused relatively lower secreted β-TG levels compared with incubation with unoxidized LDL. This fluctuation was not due to β-TG degradation by oxLDL. CONCLUSIONS: weakly activate platelets at an early stage, but then inhibit platelet function, such as aggregation and β-TG secretion.
No takes yet. Share an insight, caveat, or question.
Miyazaki et al. (2020) studied this question. Oxidized low-density lipoprotein (oxLDL) vs. Unoxidized LDL or no oxLDL was evaluated on Platelet aggregation and β-thromboglobulin (β-TG) secretion. Oxidized low-density lipoprotein weakly activated platelets at an early stage, but subsequently inhibited platelet aggregation and β-thromboglobulin secretion compared with unoxidized LDL.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: